MAOA and mechanisms of panic disorder revisited: From bench to molecular psychotherapy

Molecular Psychiatry

Volumn 19, Issue 1, 2014, Pages 122-128

  Reif, A ^a   Richter, J ^b   Straube, B ^c   Hofler M ^d   Lueken, U ^d   Gloster, A T ^d   Weber, H ^a   Domschke, K ^a,e   Fehm, L ^f   Strohle A ^g   Jansen, A ^c   Gerlach, A ^h   Pyka, M ^c   Reinhardt, I ⁱ   Konrad, C ^c,e   Wittmann, A ^g   Pfleiderer, B ^e   Alpers, G W ^j   Pauli, P ^a   Lang, T ^k   Arolt, V ^e   Wittchen, H U ^d   Hamm, A ^b   Kircher, T ^c   Deckert, J ^a   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

^j UNIVERSITY OF MANNHEIM   (Germany)

^k UNIVERSITY OF BREMEN   (Germany)

more..

Author keywords

behavioral avoidance task; fMRI; monoamine oxidase A; panic disorder; promoter polymorphism; therapygenetics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A;

ALLELE; ANTERIOR CINGULATE; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE THERAPY; CONDITIONING; CONTROLLED STUDY; EXPOSURE; FEAR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC RISK; GENOTYPE; HABITUATION; HAMILTON ANXIETY SCALE; HEART RATE; HETEROZYGOTE; HUMAN; INFERIOR PARIETAL LOBULE; MAJOR CLINICAL STUDY; MALE; MAOA GENE; MULTICENTER STUDY; NEUROIMAGING; OUTCOME ASSESSMENT; PANIC; PANIC DISORDER WITH AGORAPHOBIA; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TASK PERFORMANCE; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

AGORAPHOBIA; BRAIN; COGNITIVE THERAPY; CONDITIONING, CLASSICAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MINISATELLITE REPEATS; MONOAMINE OXIDASE; OXYGEN; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES;

EID: 84891154741     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.172     Document Type: Article

References (47)

1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679.
2. Domschke K, Reif A. Behavioral genetics of affective and anxiety disorders. Curr Top Behav Neurosci 2012; 12: 463-502.
3. Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S et al. TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 2011; 16: 647-663.
4. Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P et al. Neuropeptide S receptor gene - converging evidence for a role in panic disorder. Mol Psychiatry 2011; 16: 938-948.
5. Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J et al. Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm 2006; 113: 1921-1925.
6. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987; 48: 55-59.
7. Tyrer P, Shawcross C. Monoamine oxidase inhibitors in anxiety disorders. J Psychiatr Res 1988; 22(Suppl 1): 87-98.
8. Dickinson JL, Sale MM, Passmore A, FitzGerald LM, Wheatley CM, Burdon KP et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Exp Ophthalmol 2006; 34: 682-688.
9. Halpin C, Owen G, Gutierrez-Espeleta GA, Sims K, Rehm HL. Audiologic features of Norrie disease. Ann Otol Rhinol Laryngol 2005; 114: 533-538.
10. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993; 262: 578-580.
11. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995; 268: 1763-1766.
12. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-624.
13. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103: 273-279.
14. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000; 34: 239-244.
15. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297: 851-854.
16. Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW et al. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry 2006; 11: 903-913.
17. Reif A, Rosler M, Freitag CM, Schneider M, Eujen A, Kissling C et al. Nature and nurture predispose to violent behavior: serotonergic genes and adverse childhood environment. Neuropsychopharmacology 2007; 32: 2375-2383.
18. Maron E, Lang A, Tasa G, Liivlaid L, Toru I, Must A et al. Associations between serotonin-related gene polymorphisms and panic disorder. Int J Neuropsychopharmacol 2005; 8: 261-266.
19. Samochowiec J, Hajduk A, Samochowiec A, Horodnicki J, Stepien G, Grzywacz A et al. Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res 2004; 128: 21-26.
20. Gibbons A. American Association of Physical Anthropologists meeting. Tracking the evolutionary history of a "warrior" gene. Science 2004; 304: 818.
21. McDermott R, Tingley D, Cowden J, Frazzetto G, Johnson DD. Monoamine oxidase A gene (MAOA) predicts behavioral aggression following provocation. Proc Natl Acad Sci USA 2009; 106: 2118-2123.
22. Eisenberger NI, Way BM, Taylor SE, Welch WT, Lieberman MD. Understanding genetic risk for aggression: clues from the brain's response to social exclusion. Biol Psychiatry 2007; 61: 1100-1108.
23. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, A R Hariri, Pezawas L, Blasi G et al. Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci USA 2006; 103: 6269-6274.
24. Gloster AT, Wittchen HU, Einsle F, Hofler M, Lang T, Helbig-Lang S et al. Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia. Eur Arch Psychiatry Clin Neurosci 2009; 259(Suppl 2): S155-S166.
25. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012; 17: 236-237.
26. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T et al. Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011; 79: 406-420.
27. Richter J, Hamm AO, Pané-Farré CA, Gerlach AL, Gloster AT, Wittchen H-U et al. Dynamics of defensive reacivity in patients with panic disorder and agoraphobia: implications for the etiology of panic disorder. Biol Psychiatry 2012; 72: 512-520.
28. Reinhardt I, Jansen A, Kellermann T, Schuppen A, Kohn N, Gerlach AL et al. Neural correlates of aversive conditioning: development of a functional imaging paradigm for the investigation of anxiety disorders. Eur Arch Psychiatry Clin Neurosci 2010; 260: 443-453.
29. Kircher T, Arolt V, Jansen A, Pyka M, Reinhardt I, Kellermann T et al. Effect of cognitive-behavioral therapy on neural correlates of fear conditioning in panic disorder. Biol Psychiatry advance online publication, 23 August 2012 (e-pub ahead of print).
30. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 2001; 108: 4-32.
31. Lissek S, Rabin S, Heller RE, Lukenbaugh D, Geraci M, Pine DS et al. Overgeneralization of conditioned fear as a pathogenic marker of panic disorder. Am J Psychiatry 2010; 167: 47-55.
32. Lissek S, Rabin SJ, McDowell DJ, Dvir S, Bradford DE, Geraci M et al. Impaired discriminative fear-conditioning resulting from elevated fear responding to learned safety cues among individuals with panic disorder. Behav Res Ther 2009; 47: 111-118.
33. Tuescher O, Protopopescu X, Pan H, Cloitre M, Butler T, Goldstein M et al. Differential activity of subgenual cingulate and brainstem in panic disorder and PTSD. J Anxiety Disord 2011; 25: 251-257.
34. Mobbs D, Marchant JL, Hassabis D, Seymour B, Tan G, Gray M et al. From threat to fear: the neural organization of defensive fear systems in humans. J Neurosci 2009; 29: 12236-12243.
35. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B et al. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 2007; 317: 1079-1083.
36. Lee BT, Ham BJ. Monoamine oxidase A-uVNTR genotype affects limbic brain activity in response to affective facial stimuli. Neuroreport 2008; 19: 515-519.
37. Straube B, Chatterjee A. Space and time in perceptual causality. Front Hum Neurosci 2010; 4: 28.
38. Mueller D, Cahill SP. Noradrenergic modulation of extinction learning and exposure therapy. Behav Brain Res 2010; 208: 1-11.
39. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007; 12: 120-150.
40. de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J et al. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 2011; 108: 6621-6625.
41. Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009; 23: 350-356.
42. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U et al. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 2006; 103: 5585-5590.
43. Sehlmeyer C, Dannlowski U, Schoning S, Kugel H, Pyka M, Pfleiderer B et al. Neural correlates of trait anxiety in fear extinction. Psychol Med 2011; 41: 789-798.
44. Svensson TH. Stress, central neurotransmitters, and the mechanism of action of alpha 2-adrenoceptor agonists. J Cardiovasc Pharmacol 1987; 10(Suppl 12): S88-S92.
45. LeDoux J. The amygdala. Curr Biol 2007; 17: R868-R874.
46. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996; 54: 129-141.
47. Deakin JF, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol 1991; 5: 305-315.